AzTrials
AzTrials

Intellectual DeficiencyACCREMNCT02167568

Corpus Callosum Agenesis and Intellectual Disability

An observational study of Intellectual Deficiency and Cerebral Abnormality, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Corpus callosum agenesis or dysgenesis (CCA) is a major brain malformation (˜1/4000 births) presently diagnosed by prenatal ultrasonography. In about half of the cases, CCA is associated with other anomalies (complex CCA), which usually leads to medical abortion. Read more about this study

Who is it for?
Ages 3 months and older
Conditions the study is for
Intellectual Deficiency, Cerebral Abnormality
What is being tested?
Genetic
How many people
360 participants
Where
1 siteFrance
Study dates
Jan 2012to Jun 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 months and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: patient with corpus callosum agenesis (complete or partial) or dysgenesis associated to mental retardation recruted through pediatric neurology and genetics consultations in the reference and competence centers " intellectual disabilities of rare cause" and associated network called "DéfiSciences".

Who may be able to join

  • age > 3 months
  • patient with mental retardation
  • patient with corpus callosum agenesis (complete or partial) or dysgenesis

Who cannot join

  • Patient with corpus callosum agenesis or dysgenesis but without mental retardation
  • Patient with mental retardation but with total callosum corpus(cc)
  • Patient with corpus callosum agenesis or dysgenesis and mental retardation whose origin is acquired
  • Patient does not wish to participate, or whose parents / guardians refuse their participation
  • Patient in whom brain MRI cannot be performed
  • Patient not affiliated to a social security system (or beneficiaries who right) or CMU
  • Patient with at least one of the two parent's inclusion it not possible

Trial locations and contacts

1 site in 1 country.

France1 site
  • Groupe Hospitalier Pitié-Salpêtrière

    Paris, 75013

Other trials in France

About this study

Official title: Corpus Callosum Agenesis and Intellectual Disability: Genetic and Phenotypic Characterization

Corpus callosum agenesis or dysgenesis (CCA) is a major brain malformation (˜1/4000 births) presently diagnosed by prenatal ultrasonography. In about half of the cases, CCA is associated with other anomalies (complex CCA), which usually leads to medical abortion. Syndromes including a CCA are many (hundreds), most of which are also associated with intellectual deficiency (ID). Several genes are involved in such complex CCA. On the other hand, several studies pointed to the favorable cognitive outcome of individuals/fetuses with an apparently isolated CCA (ICCA) during pregnancy in about 70% of cases. However, there are still 30% of cases with ID or developmental delay. The precise incidence and severity of these disorders are presently unclear. Therefore, prenatal counseling of couples facing a prenatal diagnosis of ICCA is still elusive.

Our aims are to unravel the genetic causes of CCA by combining phenotypic and genetic analyses in a prospective cohort of patients with CCA and intellectual disability, in order to improve prenatal information.

Read the detailed description

Corpus callosum is the main midline brain structure connecting homologous cortical areas of both hemispheres. Corpus callosum agenesis or dysgenesis (CCA) can be diagnosed antenatally, either isolated or associated with other cerebral or extra-cerebral malformations. With an incidence of 1.8/10,000 newborn, CCA is often associated with chromosomal anomalies and mendelian syndromes. Even when CCA appears to be isolated, the neuro-developmental outcome is uncertain, with many children developing normally, and others having moderate learning disabilities or even severe ID. The genetic heterogeneity of complex CCA is large (CCA can be observed in more than 300 entities), but for many patients, no etiological diagnosis is known. Therefore, genetic counselling remains challenging in many cases. Recurrence is observed in almost 5% of cases, and for most patients with no etiological diagnosis, the disease is sporadic. These data suggest both recessive and dominant de novo inheritance.

This study aims, in a prospective cohort of 120 patients with CCA and intellectual disability:

  1. To determine the nature and the frequency of characterized genetic abnormalities.
  2. To determine the phenotypic spectrum of complex CCA
  3. To perform SNP-array analyses (i) for patients without etiological diagnosis and (ii) for patients with an identified syndrome without molecular basis to clarify the genetic basis of CCA and to evaluate the contribution of this technique in these patients
  4. To describe new clinical- genetic entities

Patients are recruited through pediatric neurology and genetics consultations in the reference and competence centers " intellectual disabilities of rare cause" and associated network called "DéfiSciences".

The workup will include for all patients :

  1. a clinical examination by a neurologist and a clinical geneticist, and a child psychiatric care if needed
  2. a blood sample for patient and his parents 2.3. a neuropsychological assessment if needed 3.4. Cerebral MRI using new technologies (diffusion, tracking fiber spectroscopy ... ) , if not available Central reviews of brain MRI are performed by a referent neuroradiologist in order to classify the type of CCA, morphological features and associated brain abnormalities.

4.5. Several additional tests could be performed if necessary:

  1. in search of associated malformations i. renal ultrasound ii. echocardiogram iii. bone x-rays iv. ophthalmological examination b. in search of neurological/sensorial dysfunction: neurophysiological assessment (electroencephalogram, brainstem evoked auditory potentials, somatosensory evoked potentials, electroretinogram and visual evoked potentials) c. Karyotype d. Molecular biology: ARX(for boys) XFRA e. Metabolic tests comprising at least plasma CK, chromatography of plasma amino acids, chromatography of urine organic acids, a redox cycle, urinary creatine and guanidinoacetic acid assay and a Bratton-Marshall test ;

After this initial assessment, investigators of the core clinical/research team will discuss all cases to validate proposed diagnoses and to determine whether a secondary assessment or complementary genetic studies are needed. Patients without established diagnosis will benefit from a study using whole genome chips (Illumina SNP-array) to be conducted at the end of the recruitment period for the second year of the project. This work will improve the essential clinical and genetic knowledge of CCA, which is necessary to improve the assessment of the prognosis in prenatal diagnosis and genetic counseling. It is also expected to expand the understanding of the complex development of the corpus callosum and its function.

Being tested
Genetic
Keywords
corpus callosum agenesis/dysgenesis, mental deficiency/ Intellectual deficiency, genetic and phenotypic characterization
Medical subject headings
Agenesis of Corpus Callosum, Congenital Abnormalities

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GeneticGenetic

Study groups in NCT02167568
Study groupRoleWhat they receive
Corpus callosum agenesis/dysgenesispatients with Corpus callosum agenesis/dysgenesis
Receives: Genetic: Genetic
parentsparents of patients with corpus callosum agenesis/dysgenesis
Receives: Genetic: Genetic

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. genetic abnormalities

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jun 2014 (estimated)
  2. Study startJan 2012
  3. Primary completionJun 2014
  4. Study completionJun 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
360 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02167568
Sponsor's protocol ID
P081260
Acronym
ACCREM
Status last verified
Jun 2014
First submitted
13 Jun 2014
Last updated
19 Jun 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Intellectual Deficiency and Cerebral Abnormality, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

genetic abnormalities (time frame: baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jun 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in